arsenic has been researched along with Granulocytic Leukemia, Chronic in 67 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (5.97) | 18.2507 |
2000's | 34 (50.75) | 29.6817 |
2010's | 28 (41.79) | 24.3611 |
2020's | 1 (1.49) | 2.80 |
Authors | Studies |
---|---|
Newman, DJ | 1 |
Du, Y; Fang, H; Xia, Y; Zhang, J | 1 |
Ayoubi, HR; Bazarbachi, AA; Bitar, NM; De Thé, HB; El Eit, RM; Iskandarani, AN; Jabbour, MN; Mahfouz, RA; Mahon, FX; Nasr, RR; Saliba, JL; Zaatari, GS | 1 |
Fei, J; Feng, M; Li, Y; Luo, X; Zhang, Y; Zhu, X | 1 |
Altman, JK; Beauchamp, E; Eklund, EA; Goussetis, DJ; Kosciuczuk, EM; Platanias, LC; Wu, EJ | 1 |
Wei, W; Wu, C; Wu, Y; Xu, W; Yan, H; Ye, C; Yu, Q | 1 |
Lei, H; Ma, CM; Song, LL; Tu, YY; Wang, WW; Wei, W; Wen, DH; Wu, YL; Xia, L; Xu, HZ | 1 |
Du, Y; Li, NN; Lyu, FF; Wang, W | 1 |
He, XW; Yan, W; Yang, W | 1 |
Fan, RF; Fang, ZG; Lin, DJ; Liu, XF; Lu, Y; Pan, GZ; Zhai, FX | 1 |
Gong, J; Meng, J; Wang, Y; Zhang, L; Zheng, S | 1 |
Chuah, C; Melo, JV | 1 |
Fang, H; Wang, K; Zhang, J | 1 |
Chen, Q; Chen, SJ; Chen, Z; Huang, QH; Liu, P; Lu, J; Mao, JH; Weng, L; Xie, YY; Zhang, QY; Zhang, Y | 1 |
Kneifel, C; Lösler, S; Rojewski, MT; Schlief, S; Schrezenmeier, H; Thiel, E | 1 |
Cortes, J; Giles, F | 1 |
Dong, D; Fei, J; Gu, J; Hu, H; Huang, K; Li, Y; Lin, C; Yao, J; Zhu, X | 1 |
Dong, D; Fei, J; Gu, J; Huang, K; Li, Y; Lin, C; Yao, J; Zhu, X | 1 |
Altman, JK; Dolniak, B; Glaser, H; Goussetis, DJ; Kroczynska, B; McNeer, JL; Platanias, LC; Sassano, A | 1 |
Essers, M; Trumpp, A; Wilson, A | 1 |
Kashimura, M; Ohyashiki, K | 1 |
Gui-Nan, L; Guo-Bao, W; Jie, L; Qi-Rong, G; Xiao-Qin, C; Yue, L | 1 |
Hirao, A; Hoshii, T; Naka, K | 1 |
Chen, Q; Chen, SJ; Chen, Z; Huang, QH; Li, KK; Liu, JX; Liu, P; Mao, JH; Sun, XY; Zhang, QY | 1 |
Chen, R; Huang, S; Li, G; Liang, Y; Liu, L; Liu, Q; Wu, Y; Yin, D; Zhang, B | 1 |
Bao, Y; Duan, Y; Kong, J; Liu, Z; Ma, X; Shan, B; Wang, Y; Wu, X | 1 |
Cao, Y; Gong, Q; Han, Z; Hong, Z; Li, C; Ma, D; Meng, L; Wu, Y; Xiao, M; Xu, D; Yang, Y; Zhou, J; Zhou, X | 1 |
Fei, J; Li, Y; Luo, X; Zhu, X | 1 |
Altman, JK; Bogyo, M; Gounaris, E; Goussetis, DJ; Platanias, LC; Sharma, B; Vakana, E; Wu, EJ | 1 |
Gounaris, E; Goussetis, DJ; Platanias, LC | 1 |
Auberger, P | 1 |
Li, H; Wang, X; Wang, Z; Xu, Z; Yue, X; Zhang, X | 1 |
Druker, BJ; Johnson, K; La Rosée, P; O'Dwyer, ME | 1 |
Choi, HI; Kim, HJ; Kim, T; Lee, IS; Shim, MJ; Yang, SJ | 1 |
Li, JE; Sun, GL; Wang, ZY; Wu, WL | 1 |
Akiharu, W; Jing, HM; Ke, XY; Yoshiro, K; Yukihiro, S | 1 |
Li, JE; Sun, GL; Wu, WL; Wu, YL | 2 |
Li, L; Zhang, R; Zhu, ZL | 1 |
Corbin, AS; Deininger, MW; Druker, BJ; Johnson, K; La Rosée, P; Mauro, MM; Melo, JV; Moseson, EM; Stoffregen, EP; Willis, S | 1 |
Bali, P; Bhalla, K; Fuino, L; Guo, F; Houghton, P; Nimmanapalli, R; O'Bryan, E; Wu, J | 1 |
Alvarez, RH; Cortes, JE; Giles, F; Kantarjian, HM; O'Brien, SM; Talpaz, M | 1 |
Chen, GQ; Chen, SJ; Chen, Z; Du, YZ; Sun, GL; Sun, HP; Wang, KK; Wu, YL; Yin, T; Zhang, J | 1 |
Chen, ZC; Li, WM; Liu, ZP; Wu, XF; You, Y; Zou, P | 1 |
Chen, WG; Gu, LJ; Jiang, LM; Ye, QD; Zhang, B; Zhao, JC; Zhao, YX | 1 |
Arthur, JS; Kannan-Thulasiraman, P; Katsoulidis, E; Platanias, LC; Tallman, MS | 1 |
Pu, Q | 1 |
Davis, RJ; Giafis, N; Higgins, LS; Katsoulidis, E; Nebreda, AR; Platanias, LC; Sassano, A; Tallman, MS | 1 |
Meng, L; Meng, R; Sui, XH; Yang, BF; Zhou, J | 1 |
Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B | 1 |
Altman, J; Giafis, N; Katsoulidis, E; Mears, H; Platanias, LC; Redig, AJ; Sassano, A; Smith, J; Tallman, MS; Yoon, P | 1 |
Bertoglio, J; Bréard, J; Potin, S | 1 |
Härtel, N; Hehlmann, R; Hochhaus, A; Konig, H; La Rosée, P; Lorentz, C; Melo, JV; Schatz, M; Schultheis, B | 1 |
Chen, GQ; Wang, LS; Wu, YL; Yu, Y | 1 |
Fu, YB; Li, CY; Li, L; Meng, FY; Song, LL; Sun, QX; Yi, ZS | 1 |
Avigan, DE; Bernardi, R; Ikeda, Y; Ito, K; Matsuoka, S; Morotti, A; Pandolfi, PP; Rosenblatt, J; Saglio, G; Teruya-Feldstein, J | 1 |
Kamada, N; Kuramoto, A; Nishimoto, Y; Shakil, FA; Yamakido, M | 1 |
Kwong, YL; Todd, D | 1 |
Bhalla, KN; Fang, G; Kim, CN; Perkins, C | 1 |
Brüggenolte, N; Güller, S; Hoelzer, D; Orleth, A; Ottmann, OG; Puccetti, E; Ruthardt, M | 1 |
Chen, G; Zhang, T; Zhou, A | 1 |
O'Dwyer, M | 1 |
Bhalla, KN; Druker, BJ; La Rosée, P; Nimmanapalli, R; O'Dwyer, ME | 1 |
Andersson, LC; Autero, M; Mustelin, T; Oetken, C; Ruutu, T; von Willebrand, M | 1 |
Goldman, JM; Gonon-Demoulian, R; Nicolini, FE | 1 |
Huang, QH; Liu, P; Luo, C; Mao, JH; Xi, XD | 1 |
Thomas, X; Troncy, J | 1 |
9 review(s) available for arsenic and Granulocytic Leukemia, Chronic
Article | Year |
---|---|
Modern traditional Chinese medicine: Identifying, defining and usage of TCM components.
Topics: Arsenicals; Artemisinins; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medicine, Chinese Traditional; Metabolomics; Stereoisomerism | 2020 |
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Topics: Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2008 |
Transcriptome and proteome analyses of drug interactions with natural products.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Discovery; Drug Synergism; Gene Expression Profiling; Herb-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Proteome; Pyrimidines; Tretinoin | 2008 |
New agents in chronic myelogenous leukemia.
Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Cytosine; Dioxolanes; Farnesyltranstransferase; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Vaccination | 2003 |
Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; beta Catenin; Bone Marrow; Cell Cycle; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Oxides; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2010 |
Investigational strategies in chronic myelogenous leukemia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Cancer Vaccines; DNA Methylation; Enzyme Inhibitors; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Research; Treatment Outcome | 2004 |
Leukemia, an effective model for chemical biology and target therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2007 |
Multifaceted approach to the treatment of bcr-abl-positive leukemias.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Treatment Outcome | 2002 |
Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Enzyme Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
1 trial(s) available for arsenic and Granulocytic Leukemia, Chronic
Article | Year |
---|---|
Effects of arsenic trioxide administration styles on leukocytosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Humans; Infusions, Intravenous; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides | 2006 |
57 other study(ies) available for arsenic and Granulocytic Leukemia, Chronic
Article | Year |
---|---|
Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Time Factors; Treatment Outcome | 2013 |
Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Bone Marrow Transplantation; Cell Transformation, Neoplastic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Oxides; Piperazines; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Survival Rate; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2014 |
VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligodeoxyribonucleotides, Antisense; Oxides; Piperazines; Pyrimidines; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Oxides; Resveratrol; Stilbenes | 2014 |
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Poly(ADP-ribose) Polymerases; Pyrazines; Pyrimidines; Reactive Oxygen Species; RNA, Messenger | 2014 |
Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Line, Tumor; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Peroxiredoxins; Reactive Oxygen Species | 2014 |
[Effect of arsenic trioxide on differentiation induction of chronic myeloid leukemia k562 cells and its potential mechanism].
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Oxides; RNA, Messenger; Transcription Factors; Up-Regulation | 2015 |
[Effect of As₂O₃on Hedgehog Pathway in Chronic Myeloid Leukemia Cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Down-Regulation; Hedgehog Proteins; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction | 2015 |
RUNX3 plays an important role in As2O3‑induced apoptosis and allows cells to overcome MSC‑mediated drug resistance.
Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Core Binding Factor Alpha 3 Subunit; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesenchymal Stem Cells; Microscopy, Fluorescence; Middle Aged; Oxides; Polymerase Chain Reaction; Young Adult | 2016 |
Induction of K562 Cell Apoptosis by As4S4 via Down-Regulating miR181.
Topics: Apoptosis; Arsenicals; Caspase 3; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Sulfides | 2017 |
A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia.
Topics: Animals; Arsenicals; Benzamides; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Piperazines; Proteasome Endopeptidase Complex; Protein Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Sulfides; Survival Rate; Systems Biology; TOR Serine-Threonine Kinases; Ubiquitins | 2009 |
Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system.
Topics: Antimony; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase Inhibitors; Caspases; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Glutathione; HL-60 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, T-Cell; Membrane Potential, Mitochondrial; Neoplasm Proteins; Oxidation-Reduction; Oxides | 2009 |
miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Proliferation; Flow Cytometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; MicroRNAs; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured | 2011 |
Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Cycle; G1 Phase; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oligonucleotides; Oxides; RNA-Binding Proteins; Up-Regulation | 2010 |
Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1.
Topics: Acetylcysteine; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dithiothreitol; Enzyme Activation; Genetic Variation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; Oxides; Phosphorylation; Protein Kinases; Reactive Oxygen Species; RNA, Small Interfering; Tretinoin; U937 Cells | 2010 |
Awakening dormant haematopoietic stem cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Growth Processes; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Mice; Oxides; Stem Cell Niche | 2010 |
Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Prognosis; Pyrimidines; Translocation, Genetic | 2010 |
Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Marrow Cells; Cell Adhesion; Cell Survival; Cells, Cultured; Coculture Techniques; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Integrin beta1; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Stromal Cells | 2010 |
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Topics: Amino Acid Sequence; Animals; Arsenicals; Fusion Proteins, bcr-abl; HeLa Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Molecular Sequence Data; Multiprotein Complexes; Protein Conformation; Proto-Oncogene Proteins c-cbl; Random Allocation; Sulfides; Ubiquitination | 2010 |
miR-153 sensitized the K562 cells to As2O3-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oxides; Real-Time Polymerase Chain Reaction | 2012 |
AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Blotting, Western; Cells, Cultured; Cytidine Deaminase; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Mutation; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.
Topics: Animals; Apoptosis; Arsenicals; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Furans; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Sulfides; TOR Serine-Threonine Kinases | 2011 |
Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; ral GTP-Binding Proteins; RNA Interference; RNA, Small Interfering | 2012 |
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 7; Cathepsin B; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysosomes; Oxides; Phosphorylation; Plasmids; Primary Cell Culture; Proteolysis; Sequestosome-1 Protein; Signal Transduction; Transfection; Ubiquitin-Activating Enzymes | 2012 |
BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Oxides; Translational Research, Biomedical | 2013 |
BCR-ABL/p62/SQSTM1: a cannibal embrace.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Signal Transduction | 2012 |
Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.
Topics: Acidithiobacillus; Antineoplastic Agents; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; RNA, Messenger; Solutions; Sulfides | 2013 |
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Biomarkers, Tumor; Caspase 3; Caspases; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Enzyme Activation; Enzyme Inhibitors; Humans; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microscopy, Electron; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinases; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines | 2002 |
Apoptotic effect of As2S2 on K562 cells and its mechanism.
Topics: Apoptosis; Arsenicals; Cell Division; Cell Survival; Fusion Proteins, bcr-abl; Genes, abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Protein-Tyrosine Kinases; RNA, Messenger; Sulfides | 2002 |
Effect of arsenic trioxide on different cell lines derived from chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Division; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; In Situ Nick-End Labeling; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Tumor Cells, Cultured | 2002 |
[Preliminary study on the molecular mechanism of K562 cell apoptosis induced by As2S2].
Topics: Apoptosis; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Sulfides | 2003 |
[Down-regulation of expression of vascular endothelial growth factor induced by arsenic trioxide in bone marrow cells of chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cells, Cultured; Child; Culture Media, Conditioned; Down-Regulation; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphokines; Male; Middle Aged; Oxides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; 5' Untranslated Regions; Apoptosis; Arsenic Trioxide; Arsenicals; Down-Regulation; Eukaryotic Initiation Factor-4E; Fusion Proteins, bcr-abl; Genes, abl; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Protein Biosynthesis; Protein Serine-Threonine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger | 2003 |
[Synergism of As2S2 and STI 571 in inducing apoptosis of K562 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Benzamides; Cell Division; Dose-Response Relationship, Drug; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenicals; Benzamides; Cell Line, Tumor; Cell Survival; DNA, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Sulfides | 2004 |
[Protein kinase C inhibitor Gö6976 sensitizes arsenic trioxide-induced cell apoptosis in chronic myeloid leukemic cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carbazoles; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Protein Kinase C; Time Factors | 2005 |
[Apoptosis mechanism in human chronic myelogenous leukemia K562 cells induced by tetra-arsenic tetra-sulfide].
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; bcl-X Protein; Blotting, Western; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfides; Time Factors | 2005 |
Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Enzyme Activation; Fibroblasts; Histones; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Knockout; Oxides; p38 Mitogen-Activated Protein Kinases; Ribosomal Protein S6 Kinases, 90-kDa; Stem Cells | 2006 |
[Further improving the standard of treatment for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cancer Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Necrosis Factor-alpha | 2006 |
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Mice; Mice, Knockout; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation | 2006 |
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine | 2006 |
Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Phosphorylation; Protein Kinases; Protein-Tyrosine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2006 |
Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 9; Humans; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Neoplasm Proteins; Oxides; Protein Serine-Threonine Kinases; rho GTP-Binding Proteins; rho-Associated Kinases | 2007 |
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Topics: Arsenic Trioxide; Arsenicals; Benzamides; Buthionine Sulfoximine; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Glutathione; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines | 2007 |
[STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Oxides; Piperazines; Pyrazines; Pyrimidines; Tumor Cells, Cultured | 2007 |
PML targeting eradicates quiescent leukaemia-initiating cells.
Topics: Adult; Animals; Arsenic Trioxide; Arsenicals; Cell Line; Coculture Techniques; Female; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Recurrence; Regeneration; Transcription Factors; Tumor Suppressor Proteins | 2008 |
Cytogenetic abnormalities of hematopoietic tissue in retired workers of the Ohkunojima poison gas factory.
Topics: Aged; Arsenicals; Bronchitis; Chromosome Aberrations; Chromosome Disorders; Chronic Disease; Female; Humans; Incidence; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mustard Gas; Occupational Diseases; Sister Chromatid Exchange; Y Chromosome | 1993 |
Delicious poison: arsenic trioxide for the treatment of leukemia.
Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Differentiation; Fatal Outcome; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Oxides; Splenomegaly | 1997 |
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; bcl-2-Associated X Protein; bcl-X Protein; Caspases; Cytochrome c Group; Cytosol; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fas Ligand Protein; fas Receptor; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, bcl-2; Histones; HL-60 Cells; Humans; Immunophenotyping; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophage-1 Antigen; Membrane Glycoproteins; Mitochondria; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oxides; Protein Biosynthesis; Protein Processing, Post-Translational; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 2000 |
BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Cells, Cultured; Colony-Forming Units Assay; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Jurkat Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Philadelphia Chromosome; Proto-Oncogene Proteins c-abl; Tumor Cells, Cultured; U937 Cells | 2000 |
[Treatment of leukemia with traditional Chinese drugs containing arsenic].
Topics: Arsenicals; Drugs, Chinese Herbal; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute | 1998 |
Phenylarsine oxide augments tyrosine phosphorylation in hematopoietic cells.
Topics: Aged; Animals; Arsenicals; Blood Platelets; Busulfan; Cell Line; Dithiothreitol; Gene Rearrangement; Granulocytes; Humans; Hydroxyurea; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Phosphates; Phosphoproteins; Phosphorylation; Phosphotyrosine; Protein Tyrosine Phosphatases; Tyrosine | 1992 |
[History of chronic myeloid leukemia: a paradigm in the treatment of cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Arsenic; Bone Marrow Transplantation; Fusion Proteins, bcr-abl; History, 19th Century; History, 20th Century; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Philadelphia Chromosome; Radiotherapy; Translocation, Genetic | 2014 |
[Role and Mechanism of the Interaction of BCR-ABL with E3 Ligase c-CBL in Targeting Therapy of Chronic Myelogenous Leukemia].
Topics: Arsenic; Fusion Proteins, bcr-abl; HeLa Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Proto-Oncogene Proteins c-cbl; Ubiquitin-Protein Ligases | 2017 |
Arsenic: a beneficial therapeutic poison - a historical overview.
Topics: Arsenic; Arsenic Poisoning; Clinical Trials as Topic; Herbal Medicine; History, 19th Century; History, 20th Century; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Materia Medica; Medicine, Traditional; Plant Preparations; Poisons; Therapeutics | 2009 |